[HTML][HTML] Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)
CC Parker, PM Petersen, AD Cook, NW Clarke… - Annals of …, 2024 - Elsevier
Background The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate
cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT …
cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT …
Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high‐risk pathologic features
BACKGROUND The 2013 American Urological Association/American Society for Radiation
Oncology consensus guidelines recommend offering adjuvant radiotherapy (RT) after …
Oncology consensus guidelines recommend offering adjuvant radiotherapy (RT) after …
[HTML][HTML] Clinicopathological significances of positive surgical resection margin after radical prostatectomy for prostatic cancers: a meta-analysis
M Kim, D Yoo, J Pyo, W Cho - Medicina, 2022 - mdpi.com
Background and Objectives: This study aims to elucidate the positive rate and the
clinicopathological significance of surgical margin after radical prostatectomy (RP) through a …
clinicopathological significance of surgical margin after radical prostatectomy (RP) through a …
The relationship between the extent of extraprostatic extension and survival following radical prostatectomy
BC Jeong, HJ Chalfin, SB Lee, Z Feng, JI Epstein… - European urology, 2015 - Elsevier
Background Subclassification of the extent of extraprostatic extension (EPE) in radical
prostatectomy (RP) specimens may enhance prognostication for prostate cancer (PCa) …
prostatectomy (RP) specimens may enhance prognostication for prostate cancer (PCa) …
Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions
RR McKay, FY Feng, AY Wang, CJD Wallis… - American Society of …, 2020 - ascopubs.org
High-risk prostate cancer accounts for approximately 15% of all prostate cancer diagnoses.
Patients with high-risk disease have an increased risk of developing biochemical …
Patients with high-risk disease have an increased risk of developing biochemical …
Recommandations en onco-urologie 2016-2018 du CCAFU: Cancer de la prostate
F Rozet, C Hennequin, JB Beauval, P Beuzeboc… - Progrès en urologie, 2016 - Elsevier
Objectives The purpose of the guidelines national committee CCAFU was to propose
updated french guidelines for localized and metastatic prostate cancer (PCa). Methods A …
updated french guidelines for localized and metastatic prostate cancer (PCa). Methods A …
Radiotherapy for recurrent prostate cancer: 2018 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group
H Lieng, AJ Hayden, DRH Christie, BJ Davis… - Radiotherapy and …, 2018 - Elsevier
The management of patients with biochemical, local, nodal, or oligometastatic relapsed
prostate cancer has become more challenging and controversial. Novel imaging modalities …
prostate cancer has become more challenging and controversial. Novel imaging modalities …
[HTML][HTML] Positive surgical margins and biochemical recurrence following minimally-invasive radical prostatectomy–an analysis of outcomes from a UK tertiary referral …
A Sachdeva, R Veeratterapillay, A Voysey, K Kelly… - BMC urology, 2017 - Springer
Background Positive surgical margins are a strong prognostic marker of disease outcome
following radical prostatectomy, though prior evidence is largely from a PSA-screened …
following radical prostatectomy, though prior evidence is largely from a PSA-screened …
Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting …
Objective After radical prostatectomy (RP), one‐third of patients will experience biochemical
recurrence (BCR), which is associated with subsequent metastasis and cancer‐specific …
recurrence (BCR), which is associated with subsequent metastasis and cancer‐specific …
Adjuvant leuprolide with or without docetaxel in patients with high‐risk prostate cancer after radical prostatectomy (TAX‐3501) Important lessons for future trials
BACKGROUND The current trial evaluated 2 common therapies for patients with advanced
prostate cancer, docetaxel and hormonal therapy (HT), in the surgical adjuvant setting …
prostate cancer, docetaxel and hormonal therapy (HT), in the surgical adjuvant setting …